These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

452 related items for PubMed ID: 24418325

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.
    Blood Adv; 2018 Oct 09; 2(19):2443-2451. PubMed ID: 30266819
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
    Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ.
    Blood; 2009 May 07; 113(19):4667-76. PubMed ID: 19050304
    [Abstract] [Full Text] [Related]

  • 8. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
    Bhattarai S, Ghannam K, Krause S, Benveniste O, Marg A, de Bruin G, Xin BT, Overkleeft HS, Spuler S, Stenzel W, Feist E.
    J Autoimmun; 2016 Dec 07; 75():118-129. PubMed ID: 27522114
    [Abstract] [Full Text] [Related]

  • 9. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.
    Blood; 2008 Sep 15; 112(6):2489-99. PubMed ID: 18565852
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):174-82. PubMed ID: 22235146
    [Abstract] [Full Text] [Related]

  • 12. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA.
    Biochem Pharmacol; 2012 Jan 15; 83(2):207-17. PubMed ID: 22027222
    [Abstract] [Full Text] [Related]

  • 13. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M, Rückrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleeft H, Ovaa H, Driessen C.
    Leukemia; 2007 Jan 15; 21(1):84-92. PubMed ID: 17024115
    [Abstract] [Full Text] [Related]

  • 14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
    Busse A, Kraus M, Na IK, Rietz A, Scheibenbogen C, Driessen C, Blau IW, Thiel E, Keilholz U.
    Cancer; 2008 Feb 01; 112(3):659-70. PubMed ID: 18181098
    [Abstract] [Full Text] [Related]

  • 16. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.
    Oncotarget; 2016 Nov 29; 7(48):78896-78909. PubMed ID: 27806331
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R.
    Leukemia; 2010 Aug 29; 24(8):1506-12. PubMed ID: 20555361
    [Abstract] [Full Text] [Related]

  • 18. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK.
    Blood; 2011 Apr 07; 117(14):3847-57. PubMed ID: 21289309
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 07; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 20. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Zang Y, Kirk CJ, Johnson DE.
    Cancer Biol Ther; 2014 Sep 07; 15(9):1142-52. PubMed ID: 24915039
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.